INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4)

Metastatic Prostate Cancer Clinical Trial

— INTERVAL  

Official title:

INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4): A Multicentre, Randomised, Controlled, Phase III Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02730338
• Other study ID #: GAP4
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 2016
• Est. completion date: October 2028

Study information

• Verified date: March 2023
• Source: Movember Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine if supervised high intensity aerobic and resistance training increases overall survival compared to self-directed exercise in patients with metastatic prostate cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 866
• Est. completion date: October 2028
• Est. primary completion date: October 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

mCRPC status:

• mCRPC patients defined as; adenocarcinoma of the prostate with systemic metastatic disease despite castrate levels of testosterone (<50 ng/dL) due to orchiectomy or LHRH agonist.

o Patients must have one or more of the following to be considered mCRPC

• Metastatic Disease Progression: >20% increase in the sum of diameters of measurable lesions from the time of maximal regression or appearance of one or more new lesions.

• Bone Scan Progression: Appearance of one or more new lesions on bone scan attributable to prostate cancer.

• PSA Progression: PSA =2 ng/ml that has risen serially on at least two occasions, each at least one week apart (PSA1 < PSA2 < PSA3).

• PSMA PET/CT scan progression: Appearance of one or more new lesions on PSMA PET/CT scan attributable to prostate cancer.

• At enrolment, mCRPC patients must fit into one of the following 5 categories:

1. Treatment naïve for mCRPC (have not yet started approved therapies for CRPC ie:

Abiraterone/Enzalutamide/Apalutamide / or Docetaxel, Cabazitaxel or other approved first line chemotherapy; less than 4 weeks on approved therapies is still considered to be treatment naïve) Or

2. Receiving Abi/Enza/Apa for mCRPC AND responding or stable (PSA values must be stable or declining after at least 4 weeks since starting Abi/Enza/Apa for mCRPC) Or

3. Patients with PSA progression while on Abi/Enza/Apa are eligible as long as they are asymptomatic AND there is no intent on starting chemotherapy within 6 months Or

4. Patients treated with Docetaxel, Cabazitaxel or other approved first line chemotherapy as first line for mCRPC who are asymptomatic without ANY evidence of progression Or

5. Patients may have progressed following first line Docetaxel, Cabazitaxel or other first line chemotherapy and are now receiving treatment with Abi/Enza/Apa. These patients must absolutely be responding or stable (PSA values must be stable or declining after starting Abi/Enza/Apa treatment) and have an estimated life expectancy of more than 1 year.

mHSPC Status:

• mHSPC patients must be classified as either high-risk or high-volume mHSPC. These groups are defined as adenocarcinoma of the prostate with systemic metastatic disease and patients also fit into one of the following 2 categories: 6. High-risk: defined as having at least 2 of three criteria: (i) Gleason score =8, (ii) presence of =3 lesions on bone scan, or (iii) presence of INTERVAL Protocol Version 5.0, 19 August 2019 4 measurable visceral lesions (PSMA PET imaging should not be used in the definition of high-risk disease) Or 7. High-volume: defined as having the presence of visceral metastases and/or = four bone metastases with at least one outside of the vertebral column and pelvis (PSMA PET imaging should not be used in the definition of high-volume disease)

Additional criteria for all groups:

• All patients will be required to be on ADT during the study period or have had a prior bilateral orchiectomy.

• Men with small cell neuroendocrine tumours or features of small cell disease are not eligible.

• =4 weeks since last major surgery and fully recovered.

• No known contraindications to high intensity exercise, including, but not limited to:

brain metastases; current congestive heart failure (New York Heart Association Class II, III or IV); serious or non-healing wound, ulcer, or bone fracture; spinal cord compromise or instrumentation due to metastatic disease; peripheral neuropathy =grade

3. No serious cardiovascular events within 12 months including, but not limited to, transient ischemic attack (TIA), cerebrovascular accident (CVA), or myocardial infarction (MI). Patients with a history of hypertension must be well-controlled (< 160/90) on anti-hypertensive therapy.

• Halabi Nomogram score <1951 (Risk Category rated as low or intermediate risk)

• Age =18 years

• Required Baseline Laboratory Values: ANC = 1500/uL; Platelet count = 100,000/uL; Creatinine = 1.5 x upper limits of normal; Bilirubin = 1.5 x upper limits of normal; AST = 1.5 x upper limits of normal; Serum testosterone = 50 ng/dL

• ECOG performance status 0-1

• Medical clearance by treating physician to undergo a symptom-limited cardiopulmonary exercise test and vigorous aerobic and resistance exercise training, and able to complete an acceptable cardiopulmonary exercise test.

• Exercise Coordination Centre (ECC) review and approval of subject's screening bone scan / areas with bone metastases.

• Men participating in vigorous aerobic exercise for >60 min/week or structured resistance exercise =2 days/week, are not eligible.

• Subject is willing and able to use technological aspects of the trial.

• The subject is fluent in the language as designated by the institution at which he would be enrolled.

Related Conditions & MeSH terms

• Metastatic Prostate Cancer
• Prostatic Neoplasms

Intervention

Behavioral:
• High intensity aerobic and resistance training

• Psychosocial support

Locations

Country	Name	City	State
Australia	Australian Prostate Cncr Research Centre	Brisbane	Queensland
Australia	University of Queensland	Brisbane	Queensland
Australia	University of Canberra	Canberra	Australian Capital Territory
Australia	Victoria University / Sunshine Hospital	Melbourne	Victoria
Australia	Edith Cowan University	Perth	Western Australia
Australia	Chris O'Brien Lifehouse	Sydney	New South Wales
Canada	University of Alberta	Edmonton	Alberta
Canada	QEII Cancer Centre / Dalhousie University	Halifax	Nova Scotia
Canada	Centre Hospitalier de l'Université de Montréal (CRCHUM)	Montreal
Germany	German Sport University Cologne	Cologne
Ireland	Trinity University	Dublin
Netherlands	Erasmus MC	Rotterdam
United Kingdom	Queen's University Belfast	Belfast
United Kingdom	University of Glasgow	Glasgow
United Kingdom	University of Surrey	Guildford	Surrey
United Kingdom	Kings College London	London
United States	UC Denver	Denver	Colorado
United States	Cedars Sinai Medical Centre	Los Angeles	California
United States	University of Minnesota	Minneapolis	Minnesota
United States	Oregon Health & Science University	Portland	Oregon
United States	UCSF	San Francisco	California
United States	Fred Hutchinson Cancer Centre	Seattle	Washington

Sponsors (5)

Lead Sponsor	Collaborator
Movember Foundation	Centre hospitalier de l'Université de Montréal (CHUM), Edith Cowan University, King's College London, University of California, San Francisco

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Germany,  Ireland,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	Overall survival will be measured from the time of randomization until death	up to 5 years
Secondary	Disease Progression	Time to disease progression will be measured from randomization until the first of the following: first CT or bone scan documenting disease progression, initiation of a new therapy for mPC (clinical progression), or first occurrence of a Symptomatic Skeletal Related Event (SSE).	up to 5 years
Secondary	Symptomatic Skeletal Related Events (SSE)	Time to first occurrence of SSE will be defined as the time from randomization to documentation of any of the following (whichever occurs first) + 1 day: Use of external beam radiation therapy to relieve bone pain; Occurrence of new symptomatic pathological bone fractures that may be vertebral or non-vertebral. Asymptomatic compression fractures detected by radiology review only will not be considered a SSE.; Spinal cord compression; Change in antineoplastic therapy to treat bone pain; Surgical intervention to treat bone pain	up to 5 years
Secondary	Opiate Use	Opiate use will be assessed via BPI-SF, the medical record review at entry with a lead-in period (<28 days). The questionnaires will be administered every three cycles until month 24, and in month 36.	up to 5 years
Secondary	Analgesic Use	Analgesic use will be assessed via BPI-SF, the World Health Organisation (WHO) analgesic scale, and medical record review at entry with a lead-in period (<28 days). The WHO analgesic scale will be completed every three cycles (based on medical review) and questionnaires will be administered every three cycles until month 24, and in month 36.	up to 5 years
Secondary	Biomarker analysis	Inflammatory and cytokine systemic milieu	up to 5 years
Secondary	Biomarker analysis	Insulin/Glucose Metabolism	up to 5 years
Secondary	Biomarker analysis	Androgen biosynthesis	up to 5 years
Secondary	Quality of Life	Physical and emotional quality of life measured by the questionnaires- Functional Assessment of Cancer Therapy- Prostate (FACT-P), Functional assessment of Chronic Illness Therapy (FACIT-Fatigue), and EuroQOL Five Dimension Questionnaire (EQ5D) will be assessed every 3 cycles.	up to 5 years
Secondary	Physical Function	Physical function will be assessed using strength assessments (1RM), a cardiopulmonary exercise test (CPET) and a functional performance test (400m walk)	up to 5 years
Secondary	Pain	Pain will be assessed via questionnaire Brief Pain Inventory- short form (BPI-SF) and medical record review at entry with a lead-in period (<28 days) and repeated measures will occur every three cycles	up to 5 years